4.0(top 10%)
impact factor
1.2K(top 20%)
papers
33.6K(top 10%)
citations
80(top 10%)
h-index
4.3(top 10%)
impact factor
1.5K
all documents
36.1K
doc citations
118(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1What are biomarkers?Current Opinion in HIV and AIDS20101,450
2Contribution of sexually transmitted infections to the sexual transmission of HIVCurrent Opinion in HIV and AIDS2010277
3Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globeCurrent Opinion in HIV and AIDS2016274
4HIV treatment as prevention and HPTN 052Current Opinion in HIV and AIDS2012230
5The global epidemic of HIV infection among men who have sex with menCurrent Opinion in HIV and AIDS2009228
6Long-acting injectable antiretrovirals for HIV treatment and preventionCurrent Opinion in HIV and AIDS2013216
7Microbial translocation and microbiome dysbiosis in HIV-associated immune activationCurrent Opinion in HIV and AIDS2016191
8Biomarkers of immune dysfunction in HIVCurrent Opinion in HIV and AIDS2010185
9Tissue reservoirs of HIVCurrent Opinion in HIV and AIDS2016183
10HIV subtype diversity worldwideCurrent Opinion in HIV and AIDS2019182
11HIV epidemics among transgender womenCurrent Opinion in HIV and AIDS2014176
12The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuitCurrent Opinion in HIV and AIDS2011175
13Human papillomavirus-related disease in people with HIVCurrent Opinion in HIV and AIDS2009167
14Evolving epidemiology of HIV-associated malignanciesCurrent Opinion in HIV and AIDS2017164
15The biology of CCR5 and CXCR4Current Opinion in HIV and AIDS2009158
16Role of acute and early HIV infection in the sexual transmission of HIVCurrent Opinion in HIV and AIDS2010155
17Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and updateCurrent Opinion in HIV and AIDS2010155
18HIV/hepatitis C coinfection natural history and disease progressionCurrent Opinion in HIV and AIDS2011154
19The mucosal barrier and immune activation in HIV pathogenesisCurrent Opinion in HIV and AIDS2008150
20Current concepts for PrEP adherence in the PrEP revolutionCurrent Opinion in HIV and AIDS2016147
21Epidemiology of HIV-associated tuberculosisCurrent Opinion in HIV and AIDS2009145
22Epidemiology and clinical characteristics of elite controllersCurrent Opinion in HIV and AIDS2011142
23Formulation and pharmacology of long-acting cabotegravirCurrent Opinion in HIV and AIDS2015139
24Th17 and regulatory T cells: implications for AIDS pathogenesisCurrent Opinion in HIV and AIDS2010137
25HIV-1-specific antibody responses during acute and chronic HIV-1 infectionCurrent Opinion in HIV and AIDS2009135
26Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccineCurrent Opinion in HIV and AIDS2010135
27HIV infection among female sex workers in concentrated and high prevalence epidemicsCurrent Opinion in HIV and AIDS2014134
28Persistent HIV-1 replication during antiretroviral therapyCurrent Opinion in HIV and AIDS2016133
29The interplay between HIV and COVID-19: summary of the data and responses to dateCurrent Opinion in HIV and AIDS2021131
30Fc receptor-mediated antiviral antibodiesCurrent Opinion in HIV and AIDS2009130
31Shocking HIV out of hidingCurrent Opinion in HIV and AIDS2016130
32Overcoming pharmacologic sanctuariesCurrent Opinion in HIV and AIDS2013128
33Where does HIV hide? A focus on the central nervous systemCurrent Opinion in HIV and AIDS2013125
34Th17 cytokines in mucosal immunity and inflammationCurrent Opinion in HIV and AIDS2010122
35Antiretrovirals and safer conception for HIV-serodiscordant couplesCurrent Opinion in HIV and AIDS2012122
36Cell-to-cell HIV-1 spread and its implications for immune evasionCurrent Opinion in HIV and AIDS2009121
37Kaposi sarcoma herpesvirus-associated cancers and related diseasesCurrent Opinion in HIV and AIDS2017120
38The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM)Current Opinion in HIV and AIDS2015119
39HIV-1 entry inhibitors: an overviewCurrent Opinion in HIV and AIDS2009118
40HIV vaccines: lessons learned and the way forwardCurrent Opinion in HIV and AIDS2010118
41Nonhuman primate models in AIDS researchCurrent Opinion in HIV and AIDS2013118
42The global epidemiology of adolescents living with HIVCurrent Opinion in HIV and AIDS2018118
43Histone deacetylase inhibitors and HIV latencyCurrent Opinion in HIV and AIDS2011116
44The role of healthcare providers in the roll out of preexposure prophylaxisCurrent Opinion in HIV and AIDS2016116
45Genital inflammation, immune activation and risk of sexual HIV acquisitionCurrent Opinion in HIV and AIDS2016115
46Th17 cell dynamics in HIV infectionCurrent Opinion in HIV and AIDS2010114
47Concentrated HIV subepidemics in generalized epidemic settingsCurrent Opinion in HIV and AIDS2014114
48History of passive antibody administration for prevention and treatment of infectious diseasesCurrent Opinion in HIV and AIDS2015114
49HIV treatment cascade in MSM, people who inject drugs, and sex workersCurrent Opinion in HIV and AIDS2015113
50Quality and quantityCurrent Opinion in HIV and AIDS2012112